Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01296815 · OUTCOME

Number of Participants With Complete Response

Intralesional Bevacizumab for Treating AIDS-associated Kaposi´s Sarcoma of the Larynx, Pharynx and Oral Cavity · Source last updated 2015-07-27

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
12 months

What was measured

Complete response will be assessed according to RECIST criteria

Groups in this outcome

HAART

Bevacizumab: Intralesional bevacizumab, dosis of 5mg/cm2, injections every 2 weeks, total number of injections: 3

HAART+ Bevacizumab Injection

Bevacizumab: Intralesional bevacizumab, dosis of 5mg/cm2, injections every 2 weeks, total number of injections: 3

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
HAART7
HAART+ Bevacizumab Injection7

Reported measurements

Source class 1
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
HAART1Not reportedNot reportedNot reportedNot reported
HAART+ Bevacizumab Injection3Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        1
      2. group Id
        OG001
        value
        3
denoms
  1. counts
    1. group Id
      OG000
      value
      7
    2. group Id
      OG001
      value
      7
    units
    Participants
description
Complete response will be assessed according to RECIST criteria
groups
  1. description
    Bevacizumab: Intralesional bevacizumab, dosis of 5mg/cm2, injections every 2 weeks, total number of injections: 3
    id
    OG000
    title
    HAART
  2. description
    Bevacizumab: Intralesional bevacizumab, dosis of 5mg/cm2, injections every 2 weeks, total number of injections: 3
    id
    OG001
    title
    HAART+ Bevacizumab Injection
param Type
NUMBER
reporting Status
POSTED
time Frame
12 months
title
Number of Participants With Complete Response
type
PRIMARY
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice